Abstract: K-Ras mutation ( mKRAS ) can result in the primary resistance of non-small cell lung carcinoma to epidermal growth factor receptor-tyrosine kinase inhibitor ( EGFR-TKI ). Due to the complexity of the KRAS pathway, the treatment of this condition has become the focus of interest and nodus of related studies. Anticancer treatments using the Ras signaling pathway as the target marker may overcome the primary resistance to EGFR-TKI. The possible targets of treatment using the Ras signaling pathway were reviewed in the present article.